New combo therapy aims to wipe out stomach cancer before surgery

NCT ID NCT07266025

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal is to see if these combinations can completely eliminate the cancer before the patient undergoes surgery. The study plans to enroll 30 adults whose cancer is locally advanced but considered removable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adebrelimab (an immunotherapy drug) combined with either chemotherapy (XELOX) or another immunotherapy (SHR-8068)
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for a specific type of stomach cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 30 participants, so results may not apply broadly. The combination therapies may cause significant side effects, and it's unknown if they will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.